Rua Bioscience (RUA) H1 2025 earnings summary

Executive summary

• Revenue increased to $693,829 for the six months ended 31 December 2024, up from $16,988 year-over-year, reflecting successful re-entry into Germany and New Zealand markets and growth in Australia.

• Net loss after tax narrowed to $1,802,255 from $10,851,830 in the prior year period, with no goodwill impairment this period versus $8.3 million previously.

• Significant capital raise completed, with $1.43 million in new share capital issued and additional funds secured post-period end to address liquidity needs.

• Facility sale remains pending after a failed settlement; management is pursuing alternative buyers and expects proceeds to support loan repayments and operations.

Financial highlights

• Revenue grew sharply to $693,829 from $16,988 year-over-year, driven by product launches in Germany, Australia, and New Zealand.

• Net loss after tax improved to $1,802,255 from $10,851,830, with basic and diluted EPS at $(0.011) versus $(0.069) year-over-year.

• Operating cash outflow was $1,942,997, an improvement from $2,131,828 in the prior year.

• Impairment expense was $24,569, significantly lower than $8,609,935 in the prior year.

• Cash and cash equivalents at period end were $538,646, down from $895,131 at 30 June 2024.

Outlook and guidance

• Management expects further revenue growth from expanded product offerings in the UK, Australia, Germany, and New Zealand.

• Ongoing capital raising and facility sale are critical to meeting operational cash needs and supporting business continuity.

• Material uncertainties remain regarding going concern, dependent on successful asset sale, capital raising, and revenue growth.